SANOFI GLOBAL HEALTH IMPROVING ACCESS NEGLECTED TO HEALTHCARE BURDEN OF NEGLECTED TROPICAL DISEASES MAINLY FOR THE MOST VULNERABLE TROPICAL DISEASES IMPACTS UNDERSERVED POPULATIONS Our Global Health entity is committed to improving access to healthcare for the most vulnerable people living in low- and middle- Neglected Tropical Diseases (NTDs) are a group of Over income countries. Working hand in hand with partners we provide 20 bacterial, parasitic, viral, and fungal infections sustainable solutions for unmet medical needs with a focus on infectious identified by the World Health Organization (WHO) 1.7 billion diseases like malaria, tuberculosis and neglected tropical diseases, and that are prevalent in many of the tropical and people are impacted (2) non-communicable diseases such as diabetes, cardiovascular diseases sub-tropical low and middle-income countries, and mental disorders. impacting more than 1.7 billion people.

These diseases can lead to lifelong disabilities, profound pain and suffering, stigma, isolation and in some cases death. In addition to their impact on health, NTDs contribute to an immense social and economic burden which perpetuates the cycle of poverty by preventing individuals from leading productive lives, and by adversely affecting families, communities, and countries as a whole.

Although many of these diseases can be prevented and/or treated successfully, and efforts are done to provide appropriate coverage, Himarkley_Getty Images. Himarkley_Getty many people affected by NTDs do not receive © the basic care they need. There is still a gap to be filled between the existing programs and the real needs to achieve their control or elimination. This has been identified in the Sustainable Development Goals (SDGs) establishing an objective of ending among others the epidemic of Neglected Tropical Diseases by 2030.

www.sanofi.com CONTACT US References: 54, rue La Boétie 1. https://unitingtocombatntds.org/london-declaration-neglected-tropical-diseases/ – 75008 Paris – France [email protected] Accessed on April 23th 2020. 2. http://end-org/ntds-in-focus/ – Accessed on April 23th 2020. Designed and product by ac-sante.com – MAT-GLB-2000375 – 07/2020. Cover: Cover: – 07/2020. ac-sante.com – MAT-GLB-2000375 by Designed and product FOCUS ON FOCUS ON

Since 2009, the innovative public-private partnership between Sanofi and DNDi has changed the history of sleeping sickness. Fexinidazole is the result of complementary competencies, which joined to reach the Xavier Vahed/DNDi Kimpavita Films-DNDi WHAT © objective of eradication © of the disease. Luc Kuykens, HO/AFP

SANOFI DOES © HUMAN AFRICAN SVP Sanofi Global Based on the positive results of the Phase II/III clinical trials completed in Health Programs the Democratic Republic of Congo (DRC) and Central African Republic, TRYPANOSOMIASIS (HAT) fexinidazole received a positive scientifi c opinion from the European Medicines Agency (EMA) in November 2018. HAT is a vector-borne parasitic disease of sub-Saharan Africa. The WHO with the support of the collaboration program, through the National Disease Almost immediately after, in December 24th 2018, a Marketing Authorization Since 2001 Sanofi has acollaboration program with the Control Program was able to ensure that all patients with sleeping sickness for Fexinidazole has been granted in DRC to treat gambiense Human African WHO in an effort to combat sleeping sickness, Leishmaniasis, received complex parenteral treatment at no cost. Through this collaboration Trypanosomiasis (HAT). Chagas disease, Buruli ulcer and Yaws. The company has the number of HAT cases reported to the WHO has been reduced by ~97% Discover the history contributed to this partnership with drug donations (such as End December 2019, the fi rst treatments of fexinidazole of the development between 2001 and 2018. This is a major achievement considering the logistics of fexinidazole pentamidine, melarsoprol, efl ornithine and today fexinidazole) arrived in Kinshasa (DRC). Through the partnership with challenge it represents. for treating patients with sleeping sickness or Human African the WHO, and in order to support international efforts for Trypanosomiasis (HAT), and fi nancial support for the execution As a further step of improvement, the collaboration with DNDi has made eliminating the disease, Sanofi is donating the drug free of of programs of the Intensive Disease Management (IDM) available the fi rst oral monotherapy for all stages of sleeping sickness, charge. The fi rst patients have already been treated. department, to an amount of US$5 million per year. fexinidazole, which allows avoiding systematic lumbar puncture for staging, Fexinidazole represents a therapeutic breakthrough and the need of mandatory hospitalization for treatment. On January 30th 2012 Sanofi , together with other pharmaceutical which will support sustainable elimination efforts as set out Find out more on how by the WHO’s roadmap for 2030. partnerships on HAT companies, donors, endemic countries and non-government are key organisations signed the London Declaration on Neglected Tropical Diseases(1) with the commitment to control, eliminate or Number of new reported cases of Human African Trypanosomiasis eradicate 10 diseases by 2020 and improve the lives of over a 40000 billion people, with clear objectives by 2020 for each of these 35000 diseases. 30000 Partnership

25000 In 2009, Drug for Neglected Diseases initiative (DNDi) and Sanofi Discover the journey 20000 of fexinidazole to Kimpavita Films-DNDi © signed a partnership for the development of fexinidazole, a new 15000 patients’ hand chemical entity for the treatment of HAT, with DNDi responsible 10000 - 97% for the clinical development and Sanofi for the industrial 5000 development, regulatory submission and supply. 0 1990 1991 1992 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018

http://apps.who.int/gho/data/node.main.A1635?lang=en – Accessed October 15th 2019.